NUR 5033 Module 5 Outcome Measurement Plan Example

Reviewed by Junia Fairbank, MSN, RN · American College of Education · Updated

This NUR 5033 Module 5 example is an outcome measurement plan that says what gets counted, by whom and against what, for faster sickle cell pain care in a composite community emergency department. It serves American College of Education NUR 5033 (NUR5033), Advanced Nursing and Practice II, in the MSN program. The plan states the local baseline and the national standard from the Yawn report first, then defines timing, process, patient outcome, safety and fidelity measures, using Donabedian to classify them and the Jungquist guideline for sedation monitoring. A separate equity measure compares patients with sickle cell disease against others with similar pain, drawing on Haywood and colleagues. Each measure has an owner, data source and frequency, read with the Perla run chart rules, and success is defined at two time points in advance. Sections typically set the number of measures.

CourseNUR 5033 Advanced Nursing and Practice II
ModuleModule 5
Paper typeOutcome measurement plan
Length1,230 words, about 4 pages plus title and reference pages
FormatAPA 7 student paper
SchoolAmerican College of Education
ProgramMSN
UpdatedOctober 2026

Free sample paper for NUR 5033 Module 5

1

What Gets Counted, by Whom and Against What: A Measurement Plan for Faster Sickle Cell Pain Care in a Community Emergency Department

Student Name

American College of Education

NUR5033: Advanced Nursing and Practice II

Module 5 Assignment

Instructor Name

August 2, 2027

What this page is doingThe title restates the module's three questions directly, which tells the grader the plan will answer each one explicitly for every measure. The APA 7 title page carries the course line and module assignment as listed.
2

The Baseline and the Standard

Two reference points anchor this plan. The first is the baseline from the first module of this course, measured over twelve months at a community emergency department that is a composite invented for the assignment: 118 visits by 41 adults with sickle cell disease in a pain crisis, a first opioid dose arriving at a median of 96 minutes after triage, 23 percent of visits treated within 60 minutes and 5 percent within 30 minutes, a pain recheck inside an hour of that dose in 42 percent and 60 percent of visits ending in admission. The second reference point is the national standard, which asks that analgesia start no more than half an hour after triage, or an hour after registration, and be followed by frequent reassessment and redosing (Yawn et al., 2014).

Every measure below is compared with one or both of these points. A measure without a comparison is a number; a measure with a baseline and a standard is evidence of change and of how far there is still to go.

What this page is doingStating both the local baseline and the national standard at the start gives every later measure its comparison point, which is exactly what against what means in the module prompt. The baseline figures are restated consistently with the first module.
3

The Measures

Timing measures are the primary measures. The first is the proportion of visits in which the first opioid dose is given within 30 minutes of triage, with the national standard as the target and the baseline of 5 percent as the starting point; the department's first-year goal is 60 percent. The second is the median time from triage to first dose, with a goal of 40 minutes or less. The third is the proportion of visits with pain and sedation reassessed within 30 minutes of the first dose, against a baseline of 42 percent within 60 minutes and a goal of 80 percent within 30. Donabedian (1988) distinguished measures of process from measures of outcome, and these timing measures are process measures chosen because the evidence links them most directly to what the change is designed to do.

The fidelity measure asks whether the protocol is being used as designed: among visits by patients who have an individualized plan, the proportion in which the documented first dose matches the plan. The outcome measures are the proportion of visits ending in admission, against the baseline of 60 percent, and the proportion of patients discharged from the department who return within 72 hours with pain, a measure that would rise if faster treatment led to premature discharge. A brief patient-reported measure, a single question asking whether the patient felt their pain was treated promptly, will be offered after each visit by text message, with responses reviewed by the patient advisory group.

The safety measures are the number of doses of naloxone given within six hours of a protocol dose and the proportion of reassessments with a sedation score indicating excessive sedation. Guidelines on opioid monitoring treat increasing sedation as the key early warning of respiratory depression (Jungquist et al., 2020), which is why sedation, not only oxygen saturation, is measured. Any naloxone administration after a protocol dose will trigger a case review within one week.

What this page is doingEach measure is defined with its comparison and target, and the timing measures are justified as process measures using a named framework. The return-visit and safety measures are chosen specifically to detect harms the change could cause, and a trigger for case review makes the safety measure actionable.
4

The Equity Measure

The gap this course set out to close was not only slow but unequal. The first module found that patients with sickle cell disease waited a median of 52 minutes longer for a first opioid dose than patients with long bone fractures at the same hospital, consistent with published evidence that patients with sickle cell disease wait longer than fracture patients even after accounting for triage level (Haywood et al., 2013). A protocol that made sickle cell care faster could still leave it slower than care for comparable pain.

The equity measure is therefore the difference in median time to first opioid dose between sickle cell pain visits and long bone fracture visits in the same month, reported monthly. The goal is to close that difference to zero within a year. A secondary equity check will compare time to first dose for the nine most frequent visitors with that for other patients with sickle cell disease, since the baseline showed the most frequent visitors waited longest. If the protocol works for everyone except the patients who come most often, it will have reproduced the old pattern in a faster form.

What this page is doingGiving equity its own measure, with a comparison group and a subgroup check drawn from the baseline findings, shows the plan is aligned with the problem as originally defined rather than only with the protocol's speed. The highlighted sentence explains why the subgroup matters.
5

Who Measures, From Where and How Often

The emergency department clinical nurse specialist owns the measurement plan. The informatics analyst will build a monthly report from the electronic record that extracts triage time, time of first opioid administration, reassessment times and scores, disposition, return visits and naloxone administration for every visit with a sickle cell diagnosis and every long bone fracture visit, so that no manual chart abstraction is needed for the core measures. The clinical nurse specialist will review a random sample of ten sickle cell visits each month by hand to confirm that the automated report is accurate and to check plan fidelity, which requires comparing the documented dose with the patient's plan.

Results will be displayed on run charts, one point per month, with the baseline median marked, and reviewed monthly by the implementation team and quarterly by the emergency department quality committee and the patient advisory group. Perla et al. (2011) present the run chart as an accessible tool for judging whether a change has shifted performance over time, using defined rules to distinguish signals from random variation. With about ten sickle cell visits a month, monthly proportions will vary widely, and the run chart rules will prevent the team from overreacting to a single good or bad month.

What this page is doingResponsibility, data source and frequency are specified for every measure, with a manual validation sample built in to check the automated report. Anticipating that small monthly numbers will fluctuate, and using run chart rules for that reason, shows statistical judgment appropriate to the setting.
6

What Would Count as Success

Deciding in advance what would count as success protects the evaluation from reading too much into early results. At six months, the change will be judged on track if the run chart shows a shift in the proportion of visits treated within 30 minutes, if fidelity to plans exceeds 80 percent and if there has been no increase in naloxone use after protocol doses. At twelve months, it will be judged successful if the 30-minute goal and the median-time goal are both met, the admission rate has fallen, 72-hour returns have not risen and the difference in median time between sickle cell and fracture visits has narrowed by at least half.

If the timing measures improve but admissions do not, the team will not conclude that the change failed. Faster treatment is a goal in its own right under the national standard, and admission decisions depend on many factors besides the first dose. If timing does not improve despite high fidelity, the team will look for the step in the process that is still causing delay, such as bed availability for monitoring, rather than abandoning the protocol.

What this page is doingDefining success at two time points, and saying in advance how mixed results will be interpreted, prevents the evaluation from being bent to fit whatever happens. This is a mark of a mature measurement plan.
7

Conclusion

The measurement plan fixes, before the change begins, what will be counted, by whom, from which data and against which baseline and standard. Timing measures show whether the change does what it was designed to do, fidelity shows whether it is being used, outcome and patient-reported measures show whether it matters to patients, safety measures catch harm and the equity measure checks that faster care is also fairer care. Displayed on run charts and reviewed by staff and patients alike, these measures will let the department see whether it has closed the gap it measured at the start of this course.

8

References

Donabedian, A. (1988). The quality of care: How can it be assessed? JAMA, 260(12), 1743-1748. https://doi.org/10.1001/jama.1988.03410120089033

Haywood, C., Jr., Tanabe, P., Naik, R., Beach, M. C., & Lanzkron, S. (2013). The impact of race and disease on sickle cell patient wait times in the emergency department. The American Journal of Emergency Medicine, 31(4), 651-656. https://doi.org/10.1016/j.ajem.2012.11.005

Jungquist, C. R., Quinlan-Colwell, A., Vallerand, A., Carlisle, H. L., Cooney, M., Dempsey, S. J., Dunwoody, D., Maly, A., Meloche, K., Meyers, A., Sawyer, J., Singh, N., Sullivan, D., Watson, C., & Polomano, R. C. (2020). American Society for Pain Management Nursing guidelines on monitoring for opioid-induced advancing sedation and respiratory depression: Revisions. Pain Management Nursing, 21(1), 7-25. https://doi.org/10.1016/j.pmn.2019.06.007

Perla, R. J., Provost, L. P., & Murray, S. K. (2011). The run chart: A simple analytical tool for learning from variation in healthcare processes. BMJ Quality & Safety, 20(1), 46-51. https://doi.org/10.1136/bmjqs.2009.037895

Yawn, B. P., Buchanan, G. R., Afenyi-Annan, A. N., Ballas, S. K., Hassell, K. L., James, A. H., Jordan, L., Lanzkron, S. M., Lottenberg, R., Savage, W. J., Tanabe, P. J., Ware, R. E., Murad, M. H., Goldsmith, J. C., Ortiz, E., Fulwood, R., Horton, A., & John-Sowah, J. (2014). Management of sickle cell disease: Summary of the 2014 evidence-based report by expert panel members. JAMA, 312(10), 1033-1048. https://doi.org/10.1001/jama.2014.10517

What the NUR 5033 Module 5 instructions ask for

NUR 5033 Module 5 typically asks you to plan how the change will be evaluated. Expect to define measures, including outcome, process and balancing or safety measures, state the baseline and comparison for each, assign responsibility and data sources, set the frequency of collection and analysis, and say what would count as success. Many prompts ask for a data collection tool or a measures table. Some ask specifically about equity. Expect roughly four pages and a measures table; the Canvas rubric sets the framework, if any, and the number of measures.

How the NUR 5033 Module 5 example is put together

The plan opens with the baseline and standard so every measure has its comparison. The measures section gives every measure a numerator, a denominator and a target, treats timing as a process measure under Donabedian's framework, and adds return visits and sedation events to detect harm, with a trigger for pausing. The equity section gives the disparity its own measure, comparing time to first dose with a matched group and checking the frequent-visitor subgroup. The responsibility section names who pulls each report, from which source and how often, builds in a manual check of the automated data and uses run chart rules for small monthly numbers. The success section defines targets at six and twelve months and says in advance how mixed results will be read.

Reading the NUR 5033 Module 5 rubric

The rubric for this plan weighs five things: fit with the original problem, the quality of each definition, a balance of measure types, the logistics of collection and success criteria. Alignment marks require measures tied to the original gap and baseline. Definition points reward numerators, denominators and comparisons. Balance marks go to process, outcome and safety measures together. Logistics points require owners, sources and frequency. Success criteria set in advance often lift a plan into the top band. Equity measures, where the problem involved a disparity, earn credit of their own. APA 7 rounds out the rubric. Giving equity its own measure, with a comparison group and a check on frequent visitors, aligns the plan with the problem defined in Module 1, which graders read for. A manual validation sample built into the reporting schedule also earns credit, because automated reports can mislabel triage times.

NUR 5033 Module 5 help: mistakes that cost points

Measurement plans most often list outcomes without definitions, baselines or owners. Another frequent weakness is measuring only speed and missing safety or fidelity. Students also forget that small numbers swing month to month and declare success after one good month. Define every measure fully. Assign a person to each. Set success criteria before you see results. If the problem involved a disparity, measure the gap itself. A measurement plan for some other change can be drafted on request to your rubric. Keep baseline figures identical to those in Module 1 so the comparison holds.

Write yours, or have the desk draft it

This paper is an original model document written by our desk, not a submitted student paper and not an official American College of Education document. Read it for the moves, then write your own to the instructions in your classroom. If you want one built to your exact prompt and rubric, the first custom sample is free and arrives in 24 to 48 hours.

More NUR 5033 and MSN sample papers

NUR 5033 Module 5 questions, answered

What is a fidelity measure?

A fidelity measure shows whether a change is being carried out as designed, for example whether the dose given matches the patient's written plan. Without it, a disappointing outcome could mean either that the change does not work or that it was not used, and you would not know which.

Why include an equity measure in a nursing project?

Because a change can improve average performance while leaving a disparity in place. If the original problem involved one group being treated more slowly or less well than another, measure the gap between them directly, using a comparison group with similar needs, so that the project shows whether care became fairer as well as faster.

Where can I find a free NUR 5033 Module 5 sample paper?

The sickle cell pain measurement plan is free here, with the baseline, each measure defined, the equity measure, owners and data sources, run chart rules and success criteria, plus five references and notes.

What is a run chart and why use one for monthly data?

A run chart plots a measure over time with its median. Simple rules, such as six points in a row above the median, signal real change. It suits small monthly numbers that swing too much for single comparisons.

How many measures should an MSN outcome plan include?

Usually five to eight: one or two outcomes, a few process measures and at least one safety or balancing measure. More measures add work without adding clarity, so choose those tied to the gap.